238 related articles for article (PubMed ID: 20616508)
21. Osilodrostat (Isturisa) for Cushing's disease.
Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
[No Abstract] [Full Text] [Related]
22. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
23. The Treatment of Cushing's Disease.
Pivonello R; De Leo M; Cozzolino A; Colao A
Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
[TBL] [Abstract][Full Text] [Related]
24. The management of Cushing's disease - from investigation to treatment.
Juszczak A; Grossman A
Endokrynol Pol; 2013; 64(2):166-74. PubMed ID: 23653280
[TBL] [Abstract][Full Text] [Related]
25. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
Fleseriu M; Petersenn S
J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
[TBL] [Abstract][Full Text] [Related]
26. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Fleseriu M; Petersenn S
Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Cushing's disease: a mechanistic update.
Cuevas-Ramos D; Fleseriu M
J Endocrinol; 2014 Nov; 223(2):R19-39. PubMed ID: 25134660
[TBL] [Abstract][Full Text] [Related]
29. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
31. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.
Truong HL; Nellesen D; Ludlam WH; Neary MP
J Med Econ; 2014 Apr; 17(4):288-95. PubMed ID: 24617917
[TBL] [Abstract][Full Text] [Related]
32. Pituitary-directed medical therapy in Cushing's disease.
Petersenn S; Fleseriu M
Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
[TBL] [Abstract][Full Text] [Related]
33. Cushing's disease.
Tritos NA; Biller BM
Handb Clin Neurol; 2014; 124():221-34. PubMed ID: 25248590
[TBL] [Abstract][Full Text] [Related]
34. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
35. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.
Simões Corrêa Galendi J; Correa Neto ANS; Demetres M; Boguszewski CL; Nogueira VDSN
Front Endocrinol (Lausanne); 2021; 12():732240. PubMed ID: 34603209
[TBL] [Abstract][Full Text] [Related]
37. Medical therapy of Cushing's disease.
Nieman LK
Pituitary; 2002; 5(2):77-82. PubMed ID: 12675504
[TBL] [Abstract][Full Text] [Related]
38. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.
Pivonello R; Ferrigno R; De Martino MC; Simeoli C; Di Paola N; Pivonello C; Barba L; Negri M; De Angelis C; Colao A
Front Endocrinol (Lausanne); 2020; 11():648. PubMed ID: 33363514
[TBL] [Abstract][Full Text] [Related]
39. Medical management of Cushing's disease.
Tritos NA; Biller BM
J Neurooncol; 2014 May; 117(3):407-14. PubMed ID: 24146187
[TBL] [Abstract][Full Text] [Related]
40. Currently used and investigational drugs for Cushing´s disease.
Ciato D; Mumbach AG; Paez-Pereda M; Stalla GK
Expert Opin Investig Drugs; 2017 Jan; 26(1):75-84. PubMed ID: 27894193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
